

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center – WO66-G609 Silver Spring, MD 20993-0002

November 21, 2014

Philips Medical Systems (Cleveland), Inc. % Ms. Catherine M. Connell Regulatory Affairs Specialist 595 Miner Road CLEVELAND OH 44143

Re: K133674

Trade/Device Name: Philips IQon Spectral CT

Regulation Number: 21 CFR 892.1750

Regulation Name: Computed tomography x-ray system

Regulatory Class: II Product Code: JAK Dated: October 23, 2014 Received: October 24, 2014

Dear Ms. Connell:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

<u>http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm</u> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Robert A Ochs

for

Janine M. Morris
Director
Division of Radiological Health
Office of In Vitro Diagnostics
and Radiological Health
Center for Devices and Radiological Health

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.

510(k) Number <i>(if known)</i> K133674
Device Name Philips IQon Spectral CT
Indications for Use (Describe) The Philips IQon Spectral CT is a Computed Tomography X-Ray System intended to produce cross-sectional images of the body by computer reconstruction of x-ray transmission data taken at different angles and planes. This device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.
The IQon Spectral CT system acquires one CT dataset – composed of data from a higher-energy detected x-ray spectrum and a lower- energy detected x-ray spectrum. The two spectra may be used to analyze the differences in the energy dependence of the attenuation coefficient of different materials. This allows for the generation of images at energies selected from the available spectrum and to provide information about the chemical composition of the body materials and/or contrast agents. Additionally, materials analysis provides for the quantification and graphical display of attenuation, material density, and effective atomic number.
This information may be used by a trained healthcare professional as a diagnostic tool for the visualization and analysis of anatomical and pathological structures.
Type of Use (Select one or both, as applicable)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."



Section 5: 510(k) Summary

[As required by 21 CFR 807.92(c)]

Applicant's Name: Philips Medical Systems (Cleveland), Inc.

Address: 595 Miner Road

Cleveland, OH 44143

USA

Telephone number: +1 440 483 3000

Contact Person: Catherine M. Connell

Title: Regulatory Affairs Specialist

Address: 595 Miner Road

Cleveland, OH 44143

USA

Telephone number: +1 440 483 5581 **Fax number:** +1 440 483 4918

E-mail: catherine.connell@philips.com

510(k) Summary 23-October-2014

Date of Preparation:

Device Trade Name: Philips IQon Spectral CT

Common or Usual Name: Computed tomography x-ray system

Classification

Name: Computed tomography x-ray system

Regulation: 21 CFR 892.1750

Class: II Product Code: JAK

Panel: Radiology

Predicate devices Philips Brilliance iCT (K131773)



Device Description:

The Philips IQon Spectral CT is a whole-body computed tomography (CT) X-Ray System featuring a continuously rotating x-ray tube and detectors gantry and multi-slice capability. The acquired x-ray transmission data is reconstructed by computer into cross-sectional images of the body taken at different angles and planes. This device also includes signal analysis and display equipment; patient and equipment supports; components; and accessories. The Philips IQon Spectral CT includes the detector array previously described in K131773 "Modified Brilliance iCT".

The IQon Spectral CT consists of three main components – a scanner system that includes a rotating gantry, a movable patient couch, and an operator console for control and image reconstruction; a Spectral Reconstruction System; and a Spectral CT Viewer. On the gantry, the main active components are the x-ray high voltage (HV) power supply, the x-ray tube, and the detection system.

In addition to the above components and the software operating them, the system includes workstation hardware and software for data acquisition; and image display, manipulation, storage, and filming, as well as post-processing into views other than the original axial images. Patient supports (positioning aids) are used to position the patient.



Intended Use:

The Philips IQon Spectral CT is a Computed Tomography X-Ray System intended to produce cross-sectional images of the body by computer reconstruction of x-ray transmission data taken at different angles and planes. This device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.

The IQon Spectral CT system acquires one CT dataset – composed of data from a higher-energy detected x-ray spectrum and a lower-energy detected x-ray spectrum. The two spectra may be used to analyze the differences in the energy dependence of the attenuation coefficient of different materials. This allows for the generation of images at energies selected from the available spectrum and to provide information about the chemical composition of the body materials and/or contrast agents. Additionally, materials analysis provides for the quantification and graphical display of attenuation, material density, and effective atomic number.

This information may be used by a trained healthcare professional as a diagnostic tool for the visualization and analysis of anatomical and pathological structures.



Substantial Equivalence:

The Philips IQon Spectral CT has an intended use and technology that are similar to the predicate device.

As described above, the Philips IQon Spectral CT includes the hardware configuration previously described in K131773 "Modified Brilliance iCT", updated system software, a Spectral Reconstruction System; and a Spectral CT Viewer application.

The IQon Spectral CT system is able to generate conventional (combined) CT images (equivalent to a CT image series from a non-spectral detector CT system) as described in K131773. The scanner software has been updated to a more recent version of software that provides for an easier user workflow (iPatient).

To address the addition of spectral CT imaging capability, a reference device has been identified. Because both devices are able to acquire two CT spectra, each is able to perform various types of spectral analysis, such as:

- Monoenergetic images
- Materials Basis/Density Pairs, such as
 - \circ 1/H₂0
 - o I/Ca
 - o Ca / Uric Acid
- Effective Atomic Number
- Material Separation/Differentiation
- Attenuation Curves
- Density Measurements/Visualization
- Reduction of Beam Hardening
- Reduction of Calcium Blooming

The Summaries of Non-Clinical Testing and Clinical Testing, presented below, provide a brief outline of the testing data that has been presented to demonstrate substantial equivalence.



Summary of Non-Clinical Testing:

The following tests demonstrated that the IQon Spectral CT system continues to conform to IEC 61223-3-5:2004:

- CT Number, Uniformity, Noise and Tomographic Section Thickness Measurements
- CTDI Dose Measurements
- Air Dose Measurements
- Spatial Resolution Measurements
- Low Contrast Detectability Measurements
- Acceptance and Constancy Test

Performance testing demonstrates following spectral capabilities:

- Monoenergetic Images keV and HU stability
- Monoenergetic Images CT linearity at 70 keV
- Iodine Quantification and Water-No-Iodine
- Iodine Map Imaging
- Calcium-No-Iodine images, and Iodine-No-Calcium images
- Calcium-No-Uric-Acid images, and Uric-Acid-No-Calcium images
- Virtual Non-Contrast (VNC) images
- Effective Atomic Number
- Beam Harding Artifact Reduction

Summary of Clinical Testing:

Clinical images were collected and analyzed, to ensure that images constructed by the IQon Spectral CT system meet user needs. This evaluation demonstrated that spectral images were useful for the visualization and analysis of anatomical and pathological structures.

Conclusion:

Philips Medical Systems (Cleveland), Inc. believes that, based on the information provided in this submission, the Philips IQon Spectral CT is substantially equivalent to its predicate devices without raising any new safety and/or effectiveness concerns.